Toxicities of dapsone in the treatment of cutaneous manifestations of rheumatic diseases
Mok, C.C.; Lau, C.S.; Wong, R.W.
Journal of Rheumatology 25(6): 1246-1247
1998
ISSN/ISBN: 0315-162X PMID: 9632100 Document Number: 484246
Document emailed within 1 workday
Related Documents
Specker, C. 2006: Cardiac manifestations of rheumatic diseases Medizinische Klinik 101(Suppl 1): 40-43Matsuo, N. 1979: Ocular manifestations in the rheumatic diseases Ryumachi 19(4): 370-378
Papadimitraki, E.D.; Kyrmizakis, D.E.; Kritikos, I.; Boumpas, D.T. 2004: Ear-nose-throat manifestations of autoimmune rheumatic diseases Clinical and Experimental Rheumatology 22(4): 485-494
Kircik, L.H. 2016: Use of Dapsone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Dapsone 5% Gel Combination Treatment Journal of Drugs in Dermatology: Jdd 15(2): 191-195
Cheong, W.Y.; Tan, K.P. 1992: Radiologic manifestations of rheumatic joint diseases in the plain radiograph Singapore Medical Journal 33(4): 395-399
Khorenian, S.D.; Lebwohl, M. 1995: New cutaneous manifestations of systemic diseases American Family Physician 51(3): 625-630
Rhein, E.; Wenig, A. 1970: Clinical experiences in the treatment of rheumatic and non-rheumatic infectious diseases with an antiphlogistic agents Zeitschrift für Allgemeinmedizin 46(29): 1464-1466
Aractingi, S.; Mansouri, S. 1997: Cutaneous manifestations related to malignant hematologic diseases Presse Medicale 26(14): 678-683
Károlyi, Z.; Erós, N.; Ujszászy, L.; Nagy, G. 2000: Cutaneous and mucosal manifestations of inflammatory bowel diseases Orvosi Hetilap 141(25): 1391-1395
Vukelja, S.J.; Sharkey, M.J.; Baker, W.J.; Berger, T.C. 1993: Pericarditis associated with acral erythema of chemotherapy: a syndrome of cutaneous and serosal toxicities? Cutis 52(2): 89-90
Bahnea, R-Gabriela.; Cârdei, E.; Luca, M.Cătălina.; Cojocaru, I.; Rîpă, C.; Luca, M. 2009: Cutaneous manifestations on toxocariasis cases hospitalized in the Paediatric Diseases Clinic of Iaşi, between 2005-2008 Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi 113(2): 428-431
Neumann, W.; Barthel, E.; Tanner, E.; Seidel, K. 1970: Gm-properties in rheumatic diseases with reference to chronic progressive polyarthritis. I. Gm(a) and Gm(x) factors in rheumatic diseases Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 25(7): 308-311
Becker, A.E.; Beekman, R.P.; van der Hal, A.L. 1976: Infantile polyarteritis nodosa and Kawasaki's disease (muco-cutaneous lymph node syndrome). 2. different diseases or manifestations of pathological process? Nederlands Tijdschrift Voor Geneeskunde 120(49): 2147-2151
Schairer, D.; Friedman, A. 2011: Manifestations and treatment of cutaneous lupus erythematosus (Part Ii of II) Journal of Drugs in Dermatology: Jdd 10(12): 1474-1476
Schairer, D.; Friedman, A. 2011: Manifestations and treatment of cutaneous lupus erythematosus (part i of II) Journal of Drugs in Dermatology: Jdd 10(10): 1212-1214
Takatsu, T.; Kino, M.; Tsujimoto, G.; Kaku, K.; Sonotani, N.; Suwa, M.; Morita, H.; Hirota, Y.; Tsutsumi, J.; Kubo, S.; Kawamura, K. 1979: Recurrence of rheumatic fever and valvular diseases--etiology of rheumatic fever, rheumatic carditis and recurrent rheumatic fever Nihon Rinsho. Japanese Journal of Clinical Medicine 37(8): 3082-3102
Dogra, J.; Lal, B.B.; Misra, S.N. 1989: Cutaneous Leishmaniasis: Therapeutic Efficacy of Dapsone in the Commonly Existing Sub-types Indian Journal of Dermatology Venereology and Leprology 55(6): 375-377
Kontic, M.; Stojanovich, L.; Mijailović-Ivković, M.; Velinović, M.; Srnka, J.; Zdravkovic, M. 2018: Are the cutaneous manifestations in patients with primary antiphospholipid syndrome a marker for predicting lung manifestations? Clinical and Experimental Rheumatology 36(1): 56-61
Vlak, T.; Pivalica, D.; Aljinović, J. 2013: Principles of extra-articular rheumatic diseases treatment--therapeutic dilemmas and treatment algorithms Reumatizam 60(2): 84-89
Wagner, I.; Heide, L. 2003: Salicin and treatment of rheumatic diseases Journal of Rheumatology 30(5): 1125